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Abstract The transformations of (E)-3-[3-(2-hydroxyaryl)-3-oxoprop-
1-en-1-yl]chromones in the presence of methylhydrazine and aromatic
bisnucleophiles are described. The reactions generally lead to chro-
mone ring transformation via pyrone ring-opening and heterocycliza-
tion to give novel diazoles and (Z)-3-aminomethylenechromanones, re-
spectively. Piperazine catalyzes chromanone ring closure of the starting
substrate to afford chromone–chromanone dyads.
Key words chromones, α,β-unsaturated carbonyl systems, Michael
additions, bisnucleophiles, X-ray diffraction, heterocycles, 2D NMR
Chromones and chromanones (2,3-dihydrochromones)
are generally recognized as medicinally active heterocy-
cles.1–3 Hence, the important biological properties of these
compounds explain their use in many synthetic scaffolds.4
Indeed, these types of compounds have long been em-
ployed in cancer therapy and anti-inflammatory drug de-
sign, especially the flavones.5 In addition to their bioactivi-
ty, chromones are used as synthetic precursors due to their
ability to undergo versatile ring transformations that utilize
the intracyclic α,β-unsaturated carbonyl system of the py-
rone ring, leading to enaminochromanones,6 aurones7 and
polyheterocyclic compounds.8
In an effort to develop novel biologically active chroma-
nones following new synthetic methods,6,9 a considerable
amount of work was focused on chromone ring modifica-
tions and transformations involving conformational rear-
rangements10 and various cyclizations through hetero-Mi-
chael additions.11a,b The large majority of reactions are ni-
trogen and oxygen nucleophilic additions promoting ring
opening of the pyrone leading to a large diversity of hetero-
cycles.5–11 A good example concerns 2-(N-methylanilino)-3-
formylchromones which have demonstrated broad synthet-
ic applications, especially when incorporating a chromone
moiety. A variety of heterocyclized chromones, novel mac-
rocycles, and tetradentate ligands can be prepared upon re-
actions with bisnucleophiles, such as hydrazines and
phenylenediamines, via substitution of the N-methylanilino
moiety and/or condensations with the 3-formyl group.12
Other studies have involved the reaction of 3-formylchro-
mones with active methylene compounds to access differ-
ent heterocyclic systems, mainly via pyrone ring-opening
upon nucleophilic attack13 with thiosemicarbazine. Further
chelation with nickel(II) yields cytotoxic and DNA-binding
agents,14 or with diazoles under microwave-assisted condi-
tions to prepare a series of chromone–diazole dyads.15
We envisaged that (E)-3-[3-(2-hydroxyaryl)-3-oxoprop-
1-en-1-yl]chromones 1a,b might undergo further transfor-
mations on reactions with bisnucleophiles at their different
electrophilic centers, namely the intracyclic α,β-unsaturat-
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ed carbonyl system (the pyrone ring) along with the exocy-
clic 3-oxoprop-1-enyl moiety. In this study, methylhydra-
zine and aromatic-derived bisnucleophiles exhibited differ-
ent reactivity toward chromones 1a,b leading to diazoles
2a,b and 3-aminomethylenechromanones 3aa,ab, respec-
tively (Scheme 1). Moderate to good yields (43–76%) were
achieved overnight at room temperature using tetrahydro-
furan as the solvent. Monitoring the reaction progress by
thin-layer chromatography showed that the best results
were obtained after stirring the reaction for 20 hours at
room temperature. Longer reaction times and higher tem-
peratures led to the formation of several other minor prod-
ucts.
Scheme 1  Synthesis of diazoles 2a,b, 3-aminomethylenechromanones 
3aa,ab, and chromone–chromanone dyads 4a,b18
The two transformations of interest involve a domino
sequence of nucleophilic attack at the chromone C-2 with
pyrone ring opening and pyrazole ring closure,16 together
with a 1,4-aza-Michael addition to the exocyclic 3-oxo-
prop-1-enyl moiety followed by formation a 2-pyrazoline
ring,17 and subsequent nucleophilic attack at the chromone
C-2 with pyrone ring opening followed by chromanone ring
closure (Scheme 2).5
It is worth noting that C-2 of chromones 1 is highly re-
active toward nucleophiles due to the presence of the oxy-
gen atom at position 1 and the mesomeric electron-with-
drawing effects caused by the two carbonyl groups. The
presence of a second electrophilic center at C-1′ on the 3-
[(2-hydroxyaryl)-3-oxoprop-1-en-1-yl] moiety of 1, even
though relatively less electrophilic, allows its participation
in a consecutive (or simultaneous) attack of a second mole-
cule of methylhydrazine to form the intermediate A. These
events are followed by heterocyclization to afford the di-
azoles 2 (Scheme 2).
The reactions of aromatic bisnucleophiles, such as
phenylenediamine and 2-aminophenol, with chromones 1
are expected to proceed through a similar mechanistic
pathway, thus favoring the initial nucleophilic attack of ni-
trogen on the chromone C-2 of the pyrone ring affording in-
termediate B. Due to the weaker nucleophilic character and
bulky nature of these bisnucleophiles, the heterocyclization
and/or attack of a second molecule on the electrophilic C-1′































a R = H 
b R = OMe 
aa R = H , X = NH2 


























Scheme 2  Probable mechanistic pathways for the formation of di-
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is not possible. Nevertheless, intermediate B was able to un-
dergo regioselective intramolecular heterocyclization via an
oxa-Michael addition using the hydroxy group of the 2-hy-
droxyphenyl side chain (resulting from the ring-opening of
the pyrone) to yield the corresponding 3-aminomethy-
lenechromanones 3 (Scheme 2).
Piperazine, taken as an example of a secondary cyclic
diamine, catalyzed the chromanone ring closure of sub-
strates 1 giving rise to the novel chromone–chromanone
dyads 4 (Schemes 1 and 2).18
2D NMR spectroscopic analysis and single-crystal X-ray
diffraction studies were employed to reveal the exact spa-
tial description of structures 2–4. Distinguishing between
the 2-(3,4-dihydro-1H-pyrazol-3-yl)phenol and 2-(1H-pyr-
azol-3-yl)phenol moieties of the diazoles 2a,b was rather
straightforward.19,20 1H NMR spectroscopic analysis clearly
showed the AMX spin-system resulting from the asymmet-
ric carbon C-3 (δC 63.8–63.9) with three doublets of dou-
blets at δH 2.97–2.98 (H-4[A]), 3.65–3.69 (H-4[M]), and
4.40–4.42 (H-3[X]). The vinylic proton H-5′ of the 1H-pyra-
zole was assigned to a singlet at δH 7.61. Nevertheless, only
analysis of the HMBC connectivities permitted the assign-
ment of the imino carbons at δC5=N 152.9–153.1 for the 3,4-
dihydro-1H-pyrazole, and at δC3′=N 148.0–147.9 for the 1H-
pyrazole, as both are involved in intramolecular hydrogen
bonding with phenolic hydroxy groups (δ2′′′-OH 10.56–10.73
and δ2′′-OH 10.56–10.97) as was clearly observed from the
crystallographic studies (vide infra). The latter proton sig-
nals could also be differentiated from their HMBC cross-
peak correlations as depicted in Figure 1.
Figure 1  Important HMBC correlations observed in the spectra of 
compounds 2a, 3aa and 4b
The 3-aminomethylenechromanones 3aa,ab21,22 dis-
played an ABX spin-system in their 1H NMR spectra (δH
3.38–3.43 and 3.69–3.71 for H-1′[AB], and 5.73–5.74 for
H-2[X]) attributed to the 2-(2-hydroxyaryl)-2-oxoethyl side
chain. It was found that the amino protons 1′′-NH appeared
as a doublet at δ1′′-NH 11.80–11.99 due to coupling with the
vinylic proton H-1′′ (JH1′′–1”NH = 12.0 Hz) which appear under
a multiplet of the aromatic protons (δH1′′ 7.35–7.57). The
HMBC connectivities allowed the unequivocal assignment
of all the non-protonated carbons (Figure 1). For example,
H-2[X] showed correlations with the neighboring carbons
C-4 (δC 181.4–181.6), C-2′ (δC 203.2–203.3), C-3 (δC 103.8–
103.9) and C-9 (δC 157.3–157.5) of the chromanone ring.
The structures of the novel chromone–chromanone dy-
ads 4a,b23,24 were established unequivocally on the basis of
1H NMR spectroscopic analysis, showing an ABX spin-sys-
tem for the intracyclic aliphatic protons H-3′[AB] and
H-2′[X] resulting from the presence of the asymmetric car-
bon at C-2′ (δC 73.0–73.1) of the chromanone unit. Carbon-
yls C-4′ (δC 191.3–191.5) and C-4 (δC 175.7) could be distin-
guished using HMBC cross-peak correlations with H-5′ and
H-5, respectively, as shown in Figure 1.
Single-crystal X-ray diffraction studies provided addi-
tional insight on the 3D structures of the chelating hexacy-
clic iminenol and enaminone systems in diazoles 2 and 3-
aminomethylenechromanones 3, respectively.
Crystals of 2a25 were isolated by slow evaporation at
6 °C from a solution of a 1:1 mixture of hexane–dichloro-
methane. The crystallographic structural features of the di-
azole 2a were in good agreement with those derived from
the 2D NMR studies (Figure 2, top). The 3,4-dihydro-1H-
pyrazole group was almost co-planar with the attached
phenol group, with the two rings subtending a dihedral an-
gle of 5.18(7)°. On the other hand, the 1H-pyrazole group
subtended a prominent 25.66(7)° angle with its corre-
sponding phenol ring. Nevertheless, as depicted in Figure 2,
both groups were engaged in O–H···N intramolecular hy-
drogen bonds. It is worth emphasizing that the bulky (3,4-
dihydro-1H-pyrazol-3-yl)phenol and (1H-pyrazol-3-
yl)phenol groups of the molecular unit of compound 2a
were located in different planes subtending a dihedral angle
of 68.10(4)°.
Crystals of 3-aminomethylenechromanone 3aa26 were
obtained from a mixture of hexane–dichloromethane (1:1)
by slow evaporation at 6 °C. Crystallographic studies clearly
showed that the chromanone and the phenylenediamine
groups were almost coplanar, with their average planes
subtending a dihedral angle of only 5.83(5)°. In addition,
the intramolecular hydrogen bonding interaction involving
these two moieties further promoted the typical Z-configu-
ration, ultimately delineating a hexacyclic enaminone ring
(Figure 2, middle). Attached to the C-2 asymmetric center,
the 2-(2-hydroxyaryl)-2-oxoethyl side chain subtended a
dihedral angle of 31.27(4)° with that formed by the conju-
gation of both the chromanone and the phenylenediamine
groups.
A similar recrystallization procedure [hexane–dichloro-
methane (1:1) at 6 °C] allowed the isolation of good quality
crystals of the novel chromone–chromanone dyad 4b.27
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chromanone average planes, joined together by the asym-
metric carbon atom, subtended an average dihedral angle
of 72.18(7)° (Figure 2, bottom).
In conclusion, (E)-3-[3-(2-hydroxyaryl)-3-oxoprop-1-
en-1-yl]chromones are very reactive substrates toward
bisnucleophiles, due to their different electron-deficient
centers. The diverse nature of their properties is notably
observed from the activated push-pull alkene systems (α,β-
unsaturated carbonyl systems), providing the ability to un-
dergo nucleophilic additions, followed by pyrone ring
opening, ultimately producing versatile intermediates
ready for heterocyclizations, thereby allowing the prepara-
tion of diazoles 2a,b, (Z)-3-aminomethylenechromanones
3aa,ab and chromone–chromanone dyads 4.
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(s, 1 H, 2′′′-OH). 13C NMR (75 MHz, CDCl3): δ = 44.3 (C-1′), 75.3
(C-2), 103.8 (C-3), 117.4 (C-3′′′′), 117.9 (C-6′′′′), 118.1 (C-4′′′′),
118.6 (C-8), 119.1 (C-5′′′), 119.5 (C-1′′′), 120.1 (C-3′′′), 121.9 (C-
6), 122.8 (C-10), 125.6 (C-5′′′′), 126.5 (C-5), 128.2 (C-1′′′′), 130.1
(C-6′′′), 134.6 (C-7), 136.9 (C-4′′′), 137.2 (C-2′′′′), 144.5 (C-1′′),
157.3 (C-9), 162.6 (C-2′′′), 181.6 (C-4), 203.3 (C-2′). HRMS (ESI):




Yield: 0.27 g (76%); Mr = 401.41 g/mol; yellow solid; mp 140–
141 °C. 1H NMR (300 MHz, CDCl3): δ = 3.38 (dd, J = 16.2, 6.6 Hz,
1 H, H-1′[AB]), 3.71 (dd, J = 16.2, 6.6 Hz, 1 H, H-1′[AB]), 5.74 (t,
J = 6.6 Hz, 1 H, H-2[X]), 6.75–6.99 (m, 6 H, H-4′′′′, H-6′′′′, H-5′′′′,
H-3′′′, H-5′′′, H-8), 7.03–7.17 (m, 2 H, H-6, H-3′′′′), 7.35–7.57 (m,
4 H, H-7, H-4′′′, H-6′′′, H-1′′), 8.01 (dd, J = 7.8, 1.7 Hz, 1 H, H-5),
11.99 (d, J = 12.0 Hz, 1 H, 1′′-NH), 12.11 (s, 1 H, 2′′′-OH). 13C NMR
(75 MHz, CDCl3): δ = 44.4 (C-1′), 75.6 (C-2), 103.9 (C-3), 114.6
(C-3′′′′), 116.2 (C-6′′′′), 118.1 (C-4′′′′), 118.6 (C-8), 119.0 (C-5′′′),
119.6 (C-1′′′), 121.3 (C-3′′′), 121.8 (C-6), 122.9 (C-10), 124.3 (C-
5′′′′), 126.6 (C-5), 128.5 (C-1′′′′), 130.1 (C-6′′′), 134.5 (C-7), 136.7
(C-4′′′), 141.8 (C-1′′), 145.5 (C-2′′′′), 157.5 (C-9), 162.7 (C-2′′′),
181.4 (C-4), 203.2 (C-2′). HRMS (ESI): m/z [M + Na]+ calcd for
C24H19NO5Na: 424.1161; found: 424.1131.
(23) 3-(4-Oxochroman-2-yl)-4H-chromen-4-one (4a)
Yield: 0.18 g (61%); Mr = 292.29 g/mol; colorless crystals; mp
195–196 °C. 1H NMR (300 MHz, CDCl3): δ = 2.89 (dd, J = 16.9,
13.0 Hz, 1 H, H-3′[AB]), 3.25 (dd, J = 16.9, 3.0 Hz, 1 H, H-3′[AB]),
5.72 (ddd, J = 13.0, 3.0, 1.0 Hz, 1 H, H-2′[X]), 7.02–7.13 (m, 2 H,
H-8′, H-6′), 7.40–7.57 (m, 3 H, H-6, H-8, H-7′), 7.72 (ddd, J = 8.7,
7.1, 1.7 Hz, 1 H, H-7), 7.95 (ddd, J = 8.6, 4.9, 3.6 Hz, 1 H, H-5′),
8.20–8.28 (m, 1 H, H-5), 8.24 (d, J = 1.0 Hz, 1 H, H-2). 13C NMR
(75 MHz, CDCl3): δ = 42.8 (C-3′), 73.0 (C-2′), 117.9 (C-8′), 118.2
(C-8), 121.1 (C-10′), 122.0 (C-6′), 122.9 (C-3), 123.8 (C-10),
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153.3 (C-2), 156.3 (C-9), 161.2 (C-9′), 175.7 (C-4), 191.3 (C-4′).
HRMS (ESI): m/z [M + Na]+ calcd for C18H12O4Na: 315.0633;
found: 315.0636.
(24) 3-(6-Methoxy-4-oxochroman-2-yl)-4H-chromen-4-one (4b)
Yield: 0.14 g (43%); Mr = 322.31 g/mol; colorless crystals; mp
195–196 °C. 1H NMR (300 MHz, CDCl3): δ = 2.85 (dd, J = 17.0,
13.1 Hz, 1 H, H-3′[AB]), 3.24 (dd, J = 17.0, 2.9 Hz, 1 H, H-3′[AB]),
3.83 (s, 3 H, 6′-OCH3), 5.67 (ddd, J = 13.1, 2.9, 1.0 Hz, 1 H, H-
2′[X]), 7.00 (d, J = 9.0 Hz, 1 H, H-8′), 7.13 (dd, J = 9.0, 3.2 Hz, 1 H,
H-7′), 7.37 (d, J = 3.1 Hz, 1 H, H-5′), 7.40–7.52 (m, 2 H, H-6, H-8),
7.72 (ddd, J = 8.6, 7.2, 1.7 Hz, 1 H, H-7), 8.21–8.28 (m, 1 H, H-5),
8.24 (d, J = 1.0 Hz, 1 H, H-2). 13C NMR (75 MHz, CDCl3): δ = 42.7
(C-3′), 55.8 (6′-OCH3) 73.1 (C-2′), 107.6 (C-5′), 118.2 (C-8), 119.2
(C-8′), 121.0 (C-10′), 123.0 (C-3), 123.8 (C-10), 125.2 (C-7′),
125.5 (C-6), 125.9 (C-5), 134.0 (C-7), 153.3 (C-2), 154.5 (C-6′),
155.8 (C-9′), 156.3 (C-9), 175.7 (C-4), 191.5 (C-4′). HRMS (ESI):
m/z [M + Na]+ calcd for C19H14O5Na: 345.0739; found: 345.0748.
(25) Crystal data for compound 2a (CCDC 1404991): C20H20N4O2,
M = 348.40, triclinic, space group Pī, Z = 2, a = 8.7610(13) Å,
b = 9.9194(16) Å, c = 11.871(2) Å, α = 66.580(7)°, β = 70.069(7)°,
γ = 74.993(7)°, V = 880.8(3) Å3, μ(Mo-Kα) = 0.088 mm–1,
Dc = 1.314 g cm–3, colorless block, crystal size =
0.22 × 0.16 × 0.10 mm3. Of a total of 19322 reflections collected,
4753 were independent (Rint = 0.0413). Final R1 = 0.0467
[I > 2σ(I)] and wR2 = 0.1267 (all data). Data completeness to
θ = 25.24°, 99.9%.
(26) Crystal data for compound 3aa (CCDC 1404990): C24H20N2O4,
M = 400.42, monoclinic, space group P21/n, Z = 4,
a = 14.9755(11) Å, b = 4.7510(3) Å, c = 26.6395(16) Å,
β = 93.664(5)°, V = 1891.5(2) Å3, μ(Mo-Kα) = 0.097 mm–1,
Dc = 1.406 g cm–3, orange plate, crystal size of 0.22 × 0.12 × 0.03
mm3. Of a total of 15482 reflections collected, 4999 were inde-
pendent (Rint = 0.0475). Final R1 = 0.0505 [I > 2σ(I)] and
wR2 = 0.1233 (all data). Data completeness to θ = 25.24°, 99.6%.
(27) Crystal data for compound 4b (CCDC 1404989): C19H14O5,
M = 322.30, triclinic, space group Pī, Z = 2, a = 8.4108(9) Å,
b = 8.5434(9) Å, c = 10.6878(11) Å, α = 83.293(3)°,
β = 72.084(3)°, γ = 82.141(3)°, V = 721.61(13) Å3, μ(Mo-Kα) =
0.108 mm–1, Dc = 1.483 g cm–3, colorless plate, crystal size of
0.16 × 0.12 × 0.07 mm3. Of a total of 13854 reflections collected,
2640 were independent (Rint = 0.0256). Final R1 = 0.0553
[I > 2σ(I)] and wR2 = 0.1356 (all data). Data completeness to
θ = 25.24°, 99.6%.
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